AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6619041 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin and Carbenicillin
Number of subjects: 0
Study 31476795 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Port Laparoscopic Cholecystectomy (RPLC)
Number of subjects: 20
Study 31476795 — intervention group
Group type: COMPARATOR
Intervention: Standard four‐port cholecystectomy (4LP)
Number of subjects: 20
Study 28459155 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, exercise‐focused, self‐management program (MMOVeS)
Number of subjects: 49
Study 28459155 — intervention group
Group type: COMPARATOR
Intervention: Exercise information booklet (Control)
Number of subjects: 49
Study 25935085 — intervention group
Group type: EXPERIMENTAL
Intervention: Veneered zirconia (VZ) crowns made of zirconia frameworks veneered with CAD/CAM‐produced lithium disilicate ceramic
Number of subjects: 60
Study 25935085 — intervention group
Group type: COMPARATOR
Intervention: Monolithic lithium disilicate (MLD) crowns
Number of subjects: 60
Study 25079593 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomyocardial injection of BM cells (100 million, n=19)
Number of subjects: 28
Study 25079593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=9)
Number of subjects: 28
Study 21990263 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (2-8 pmol/min)
Number of subjects: 22
Study 21990263 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (5-20 µg/min)
Number of subjects: 22
Study 21990263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemia-reperfusion injury
Number of subjects: 22
Study 21990263 — intervention group
Group type: COMPARATOR
Intervention: Ischaemic preconditioning (local or remote)
Number of subjects: 22
Study 19549739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (22.5 mg as Nitro-Bid)
Number of subjects: 186
Study 19549739 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 186
Study 17762000 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for type 2 diabetes
Number of subjects: 23
Study 17762000 — intervention group
Group type: EXPERIMENTAL
Intervention: First screening test
Number of subjects: 23
Study 17762000 — intervention group
Group type: EXPERIMENTAL
Intervention: Final diagnostic test
Number of subjects: 23
Study 17762000 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-diagnosis for screen detected type 2 diabetes
Number of subjects: 23
Study 17762000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate results
Number of subjects: 23
Study 17762000 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative screening results
Number of subjects: 23
Study 14965849 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Intervention‐‐Problem Solving (TIPS) with face-to-face meetings
Number of subjects: 0
Study 14965849 — intervention group
Group type: COMPARATOR
Intervention: Telephone Intervention‐‐Problem Solving (TIPS) without face-to-face meetings (Control)
Number of subjects: 0
Study 14965849 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Intervention‐‐Problem Solving (TIPS)
Number of subjects: 0
Study 11749950 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs), administered twice daily for 12 weeks or longer
Number of subjects: 0
Study 9760605 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phacoemulsification and trabeculectomy (PEM/TRAB) with mitomycin-C
Number of subjects: 42
Study 9760605 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy (TRAB) with mitomycin-C
Number of subjects: 42
Study 8139476 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrolipstatin (THL)
Number of subjects: 17
Study 2850891 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B sulphate ophthalmic ointment 4-times a day for 7 days
Number of subjects: 42
Study 2850891 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol ophthalmic ointment 4-times a day for 7 days
Number of subjects: 42
Study 31856882 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE 'Steps to Success' programme
Number of subjects: 37
Study 28179074 — intervention group
Group type: EXPERIMENTAL
Intervention: Erroneous examples
Number of subjects: 36
Study 28179074 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct examples
Number of subjects: 36
Study 28179074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no examples)
Number of subjects: 36
Study 26307903 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-daily human regular U-500 insulin (U-500R)
Number of subjects: 162
Study 26307903 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily human regular U-500 insulin (U-500R)
Number of subjects: 162
Study 26307903 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-daily and twice-daily human regular U-500 insulin (U-500R)
Number of subjects: 162
Study 23212456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients
Number of subjects: 139
Study 23212456 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 139
Study 21665223 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (400 mg) or ground dried fish (529 ± 109 mg)
Number of subjects: 358
Study 21665223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 18290842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 420 units
Number of subjects: 125
Study 18290842 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 210 units
Number of subjects: 125
Study 18290842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 16494642 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum
Number of subjects: 0
Study 15013270 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective caesarean section under nitrous oxide general anesthesia
Number of subjects: 50
Study 15013270 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 50
Study 15013270 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective caesarean section under nitrous oxide general anesthesia (cord plasma)
Number of subjects: 50
Study 15013270 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery (cord plasma)
Number of subjects: 50
Study 10938448 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking ad libitum
Number of subjects: 0
Study 10938448 — intervention group
Group type: COMPARATOR
Intervention: 24-hour abstinence prior to data collection
Number of subjects: 0
Study 10938448 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-to-late follicular (MLF) phase
Number of subjects: 0
Study 10938448 — intervention group
Group type: EXPERIMENTAL
Intervention: Late luteal (LL) phase
Number of subjects: 0
Study 10938448 — intervention group
Group type: COMPARATOR
Intervention: 24-hour abstinence
Number of subjects: 0
Study 10938448 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking ad libitum and 24-hour abstinence
Number of subjects: 0
Study 8923071 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin-coated catheters (T; n = 10)
Number of subjects: 20
Study 8923071 — intervention group
Group type: COMPARATOR
Intervention: Control catheters (C; n = 10)
Number of subjects: 20
Study 1409487 — intervention group
Group type: COMPARATOR
Intervention: Three middle-school interventions adopted by Minnesota school districts as a result of the 1985 legislation.
Number of subjects: 48
Study 1409487 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota legislative initiative for tobacco use prevention.
Number of subjects: 48
Study 3002167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone (2 mg)
Number of subjects: 24
Study 3002167 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine (15 mg)
Number of subjects: 24
Study 31274267 — intervention group
Group type: EXPERIMENTAL
Intervention: ANI group
Number of subjects: 72
Study 31274267 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI group
Number of subjects: 72
Study 31274267 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 31274267 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cortisol levels
Number of subjects: 72
Study 31274267 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain scores
Number of subjects: 72
Study 28032481 — intervention group
Group type: EXPERIMENTAL
Intervention: SER100 (10 mg)
Number of subjects: 17
Study 28032481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 26301645 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC (N-acetylcysteine) with sustained sodium chloride regime (1 mL/kg/h for 12 hours before, during, and 6 hours after the procedure) and oral NAC at 1.2 g bid for 3 days (n = 185)
Number of subjects: 548
Study 26301645 — intervention group
Group type: EXPERIMENTAL
Intervention: SOB (sodium bicarbonate) with abbreviated SOB regime (3 mL/kg/h 1 hour before the procedure, and 1 mL/kg/h during and 6 hours after the procedure) (n = 182)
Number of subjects: 548
Study 26301645 — intervention group
Group type: EXPERIMENTAL
Intervention: COM (combination of abbreviated SOB regime and oral NAC) (n = 181)
Number of subjects: 548
Study 26301645 — intervention group
Group type: COMPARATOR
Intervention: NAC
Number of subjects: 548
Study 26301645 — intervention group
Group type: COMPARATOR
Intervention: COM
Number of subjects: 548
Study 26301645 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC, SOB, COM
Number of subjects: 548
Study 24623848 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants reflecting higher vitamin E status (specifically SNP rs964184)
Number of subjects: 1025
Study 24623848 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs964184 among homozygous carriers of the minor allele
Number of subjects: 1025
Study 24623848 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs11057830 in SCARB1
Number of subjects: 1025
Study 22193935 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed walking paced by a metronome (Group A₁)
Number of subjects: 47
Study 22193935 — intervention group
Group type: COMPARATOR
Intervention: Walking a known distance in a fixed time (Group A₂)
Number of subjects: 47
Study 19508995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of BMMNC (n = 41)
Number of subjects: 86
Study 19508995 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, n = 45)
Number of subjects: 86
Study 16396971 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous darbepoetin alfa (32.1 microg/week)
Number of subjects: 71
Study 16396971 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous darbepoetin alfa (34.1 microg/week)
Number of subjects: 71
Study 14607958 — intervention group
Group type: EXPERIMENTAL
Intervention: C5a receptor antagonist (10 mg/kg/day peroral, 0.3 mg/kg/day s.c.)
Number of subjects: 0
Study 14607958 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg/day s.c.)
Number of subjects: 0
Study 14607958 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg i.v.)
Number of subjects: 0
Study 14607958 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of C5a antagonist and prednisolone
Number of subjects: 0
Study 14607958 — intervention group
Group type: COMPARATOR
Intervention: Colitis control (drug-free)
Number of subjects: 0
Study 10917389 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 30
Study 10917389 — intervention group
Group type: COMPARATOR
Intervention: Population model
Number of subjects: 30
Study 8930228 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/d CNA (ENDURACIN) for 2 months
Number of subjects: 89
Study 8930228 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg/d CNA for 2 months
Number of subjects: 89
Study 8930228 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (American Heart Association Step I Diet) for 8 weeks
Number of subjects: 89
Study 1357453 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (10 mg bolus followed by 3.2 mg/h intravenously for 72 hours)
Number of subjects: 1005
Study 1357453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1005
Study 4054430 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 10
Study 30776253 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 15
Study 30776253 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 15
Study 29749688 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced aphasia therapy (CIAT)
Number of subjects: 20
Study 29749688 — intervention group
Group type: COMPARATOR
Intervention: Stimulation aphasia therapy (SAT)
Number of subjects: 20
Study 29749688 — intervention group
Group type: EXPERIMENTAL
Intervention: CIAT followed by SAT (C1S2 group)
Number of subjects: 20
Study 29749688 — intervention group
Group type: COMPARATOR
Intervention: SAT followed by CIAT (S1C2 group)
Number of subjects: 20
Study 25833808 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Education (PSE) among mothers with non-avoidant coping
Number of subjects: 93
Study 25833808 — intervention group
Group type: COMPARATOR
Intervention: Non-avoidant controls
Number of subjects: 93
Study 25833808 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Education (PSE) among mothers with avoidant coping
Number of subjects: 93
Study 25833808 — intervention group
Group type: COMPARATOR
Intervention: Avoidant controls
Number of subjects: 93
Study 25310146 — intervention group
Group type: EXPERIMENTAL
Intervention: IL1 beta gene polymorphisms SNP‐511
Number of subjects: 115
Study 25310146 — intervention group
Group type: EXPERIMENTAL
Intervention: IL1 beta gene polymorphisms SNP+3953
Number of subjects: 115
Study 25310146 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype C‐511C
Number of subjects: 115
Study 25310146 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype C+3953C
Number of subjects: 115
Study 22057730 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of water
Number of subjects: 15
Study 22057730 — intervention group
Group type: COMPARATOR
Intervention: 50 ml of water (control)
Number of subjects: 15
Study 20730260 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 40
Study 20730260 — intervention group
Group type: COMPARATOR
Intervention: No ischemic preconditioning
Number of subjects: 40
Study 18602083 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded aerobic exercise test on a cycle ergometer with breath-by-breath gas measurements and continuous heart rate monitoring
Number of subjects: 24
Study 18602083 — intervention group
Group type: COMPARATOR
Intervention: Graded aerobic exercise test on a cycle ergometer
Number of subjects: 24
Study 16052584 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy (etanercept and infliximab)
Number of subjects: 353
Study 12444542 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg daily, increased to 10 mg daily if necessary after 6 weeks)
Number of subjects: 222
Study 12444542 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS (30 mg daily, increased to 60 mg daily if necessary after 6 weeks)
Number of subjects: 222
Study 12444542 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 222
Study 12444542 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 222
Study 10363563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase II (NOS II)
Number of subjects: 0
Study 10363563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase I (NOS I)
Number of subjects: 0
Study 10363563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase III (NOS III)
Number of subjects: 0
Study 10363563 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS expression in clear-cell adenocarcinomas and serous-type adenocarcinomas
Number of subjects: 0
Study 10363563 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS expression in uterine squamous carcinomas and endometrial adenocarcinomas
Number of subjects: 0
Study 10363563 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of NOS expression with patients' age or clinical stage
Number of subjects: 0
Study 7561417 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic double-finger bandage
Number of subjects: 0
Study 7561417 — intervention group
Group type: COMPARATOR
Intervention: Aluminium splint
Number of subjects: 0
Study 1935151 — intervention group
Group type: EXPERIMENTAL
Intervention: Double lumen umbilical venous catheters
Number of subjects: 43
Study 1935151 — intervention group
Group type: COMPARATOR
Intervention: Single lumen umbilical venous catheters
Number of subjects: 43
Study 7020194 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation of the larynx and all neck nodes (T+N), tumor dose 5130 rad/6‐7 weeks
Number of subjects: 152
Study 7020194 — intervention group
Group type: COMPARATOR
Intervention: Irradiation of the laryngeal portals only (T), tumor dose 5130 rad/5 weeks
Number of subjects: 152
Study 31675636 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct referral to Physical Activity Guidelines (PAGs) from a physician (REF)
Number of subjects: 91
Study 31675636 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) given a print copy of PAGs
Number of subjects: 91
Study 30136445 — intervention group
Group type: EXPERIMENTAL
Intervention: dHACM
Number of subjects: 110
Study 30136445 — intervention group
Group type: COMPARATOR
Intervention: no-dHACM
Number of subjects: 110
Study 28693525 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based peer support
Number of subjects: 1269
Study 28693525 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based peer support
Number of subjects: 1269
Study 28693525 — intervention group
Group type: COMPARATOR
Intervention: Standard of care under Option B+
Number of subjects: 1269
Study 26540987 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medical therapies and autologous BM-MNC transplantation
Number of subjects: 61
Study 26540987 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapies
Number of subjects: 61
Study 24263273 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3-millisecond ultrabrief-pulse ECT
Number of subjects: 40
Study 24263273 — intervention group
Group type: COMPARATOR
Intervention: 1-millisecond brief-pulse ECT
Number of subjects: 40
Study 21170641 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified ice cream containing 96, 244, 459 or 676 mg calcium daily for 28 days
Number of subjects: 80
Study 21170641 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified ice cream (244 mg calcium preparation)
Number of subjects: 80
Study 19366270 — intervention group
Group type: EXPERIMENTAL
Intervention: HairMax LaserComb
Number of subjects: 110
Study 19366270 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 110
Study 17435563 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 30
Study 17435563 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 17435563 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 30
Study 12610326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (prokinetic)
Number of subjects: 23
Study 12610326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10509847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 14 mg/kg QD
Number of subjects: 792
Study 10509847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 7 mg/kg BID
Number of subjects: 792
Study 10509847 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 10 mg/kg 4 times daily
Number of subjects: 792
Study 8568623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual oxytocin (400 int. units / 684 micrograms)
Number of subjects: 6
Study 8568623 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin (1 int. unit / 1.71 micrograms)
Number of subjects: 6
Study 1848716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethiodized poppy‐seed oil
Number of subjects: 398
Study 1848716 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble contrast media (Iohexol, Ioxaglate, Diatrizoate meglumine)
Number of subjects: 398
Study 7006790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with 5-FU (9 mg/kg intravenously for five consecutive days) and CCNU (70 mg/m2 orally on the first day of each course).
Number of subjects: 152
Study 7006790 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (control group).
Number of subjects: 152
Study 7006790 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with 5-FU and CCNU.
Number of subjects: 152
Study 31935388 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal counseling and postpartum intrauterine device (PPIUD) insertion services
Number of subjects: 75293
Study 31935388 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal counseling
Number of subjects: 75293
Study 31039164 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-liposomal nano-sized glutathione (NLNG) 200mg
Number of subjects: 15
Study 31039164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28506979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe added to simvastatin therapy
Number of subjects: 0
Study 28506979 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin-placebo
Number of subjects: 0
Study 26610355 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-technical skills coaching after each of 5 simulated operations
Number of subjects: 16
Study 26610355 — intervention group
Group type: COMPARATOR
Intervention: Self-reflection after each of 5 simulated operations (Control)
Number of subjects: 16
Study 23222037 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help (INT-GSH)
Number of subjects: 155
Study 23222037 — intervention group
Group type: COMPARATOR
Intervention: Conventional guided bibliotherapy (BIB-GSH)
Number of subjects: 155
Study 21355446 — intervention group
Group type: EXPERIMENTAL
Intervention: New pharmaceutical equivalent tablet formulation containing 300 mg of TDF
Number of subjects: 40
Study 21355446 — intervention group
Group type: COMPARATOR
Intervention: Innovator product
Number of subjects: 40
Study 19113000 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated turning using an air-cell mattress
Number of subjects: 10